| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney. Buthiazide inhibits the reabsorption of sodium and chloride ions in the distal convoluted tubules. Its mode of action involves inhibiting the sodium-chloride symporter. The compound affects renal epithelial cells by altering ion transport and cellular metabolism.
|
|---|---|
| ln Vitro |
Buthiazide inhibits sodium reabsorption in the distal convoluted tubules of the kidneys, promoting the excretion of sodium and water, thereby reducing blood pressure and fluid retention. It works by inhibiting the sodium-chloride symporter. The compound affects renal epithelial cells by altering ion transport and cellular metabolism.
|
| ln Vivo |
In vivo, buthiazide is used as a thiazide diuretic to treat hypertension and edema associated with congestive heart failure, liver cirrhosis, and renal disorders. It reduces blood pressure and fluid retention by promoting the excretion of sodium and water. The compound is used in cardiovascular and renal research.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for buthiazide involve measuring its inhibition of the sodium-chloride symporter in renal epithelial cells. Cells expressing the symporter are treated with buthiazide, and sodium or chloride uptake is measured using fluorescent or radioactive tracers. The compound's ability to inhibit ion transport is assessed.
|
| Cell Assay |
In vitro cellular assays for buthiazide involve treating renal epithelial cells with the compound and measuring ion transport, cell volume, or cellular metabolism. Cells are treated with various concentrations of buthiazide, and sodium or chloride uptake is measured. The compound's effects on cell function and ion homeostasis are evaluated.
|
| Animal Protocol |
In vivo animal studies for buthiazide typically involve administration to hypertensive animal models to assess its diuretic and antihypertensive effects. Blood pressure, urine output, and electrolyte excretion are measured. Buthiazide reduces blood pressure and promotes sodium and water excretion.
|
| ADME/Pharmacokinetics |
Buthiazide has a molecular weight of 353.85 and a molecular formula of C11H16ClN3O4S2. It is a thiazide diuretic that is orally active. The compound is used in cardiovascular and renal research. Further pharmacokinetic studies are needed to fully characterize its absorption, distribution, metabolism, and elimination.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of buthiazide have established its safety profile for use as a diuretic and antihypertensive agent. The compound is generally well tolerated at therapeutic doses. Common adverse effects may include electrolyte imbalances, dehydration, and metabolic changes. The compound should be used under appropriate medical supervision.
|
| Additional Infomation |
Butizide is a benzothiadiazine drug.
Buthiazide (Butizide) is a thiazide diuretic and a 3-isobutyl analog of hydrochlorothiazide used to treat hypertension and edema. It works by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, promoting the excretion of sodium and water. Buthiazide is used in cardiovascular and renal research to study electrolyte transport, renal function, and blood pressure regulation. |
| Molecular Formula |
C11H16CLN3O4S2
|
|---|---|
| Molecular Weight |
353.83
|
| Exact Mass |
353.027
|
| CAS # |
2043-38-1
|
| PubChem CID |
16274
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.433g/cm3
|
| Boiling Point |
562.7ºC at 760mmHg
|
| Melting Point |
214-217ºC
|
| Flash Point |
294.1ºC
|
| Vapour Pressure |
1.09E-12mmHg at 25°C
|
| Index of Refraction |
1.572
|
| LogP |
4.392
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
582
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(CC1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(N)=O)Cl)C
|
| InChi Key |
HGBFRHCDYZJRAO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H16ClN3O4S2/c1-6(2)3-11-14-8-4-7(12)9(20(13,16)17)5-10(8)21(18,19)15-11/h4-6,11,14-15H,3H2,1-2H3,(H2,13,16,17)
|
| Chemical Name |
6-chloro-3-(2-methylpropyl)-1,1-dioxo-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide
|
| Synonyms |
Butizidum S 3500SaltucinS-3500EunephranS3500 Butizide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8262 mL | 14.1311 mL | 28.2622 mL | |
| 5 mM | 0.5652 mL | 2.8262 mL | 5.6524 mL | |
| 10 mM | 0.2826 mL | 1.4131 mL | 2.8262 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
